Back to search

University of Sheffield

Optimising Techniques for CRISPR/Cas9 Genome Editing as Treatment for Haemoglobinopathies

Abstract

dc:description.abstract

The problem: Sickle cell disease and β (beta) thalassaemia are among the most common monogenic disorders worldwide, causing significant morbidity and early mortality in affected patients. Both are caused by mutations (including deletions in the case of β thalassaemia) in the β globin gene (HBB), resulting in abnormal or reduced haemoglobin, respectively. The solution: Over recent decades, genome modification strategies have been developed with the aim of providing long-term amelioration of these conditions without the need for a bone marrow (BM) transplant. One such strategy involves targeted genome editing with the aim of reinducing foetal haemoglobin, which is known to improve symptoms. Hypothesis: HbF reinduction can be maximised by application of a multiplex genome editing strategy targeting both HBG promoter and BCL11A erythroid enhancer regions. Methods: CRISPR/Cas9 editing strategies targeting the HBG-113 and BCL11A-ee regions individually, or together either simultaneously or sequentially, were compared in terms of editing efficiencies (by TIDE analysis (Tracking of Indels by Decomposition) after Sanger sequencing) and HbF reinduction (by flow cytometry and high-performance liquid chromatography). Translocation events were measured qualitatively and then quantitatively by standard polymerase chain reaction (PCR) and digital droplet PCR respectively. Experiments were conducted in vitro using human haematopoietic stem and progenitor cells (HSPCs), and in vivo using the humanised mouse model. Results and Conclusion: Maximum HbF reinduction was observed with the sequential dual editing strategy, which also demonstrated an acceptable cytotoxicity profile and engraftment in vivo. However, dual editing was associated with the development of chromosomal translocations, which persisted in vivo and preclude the further development of such a multiplex editing strategy in this context.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Sheffield
Year dc:date.issued
2022

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Samuelson, Clare
Advisors dc:contributor.advisor
  • Lawson, Michelle
  • Chantry, Andrew
  • Wright, Josh
  • Snowden, John

Rights

Language dc:language.dcterms_iso639_2
eng

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Samuelson, Clare. Optimising Techniques for CRISPR/Cas9 Genome Editing as Treatment for Haemoglobinopathies. doctoral thesis, University of Sheffield, 2022.